RU2012127383A - Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке - Google Patents
Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке Download PDFInfo
- Publication number
- RU2012127383A RU2012127383A RU2012127383/10A RU2012127383A RU2012127383A RU 2012127383 A RU2012127383 A RU 2012127383A RU 2012127383/10 A RU2012127383/10 A RU 2012127383/10A RU 2012127383 A RU2012127383 A RU 2012127383A RU 2012127383 A RU2012127383 A RU 2012127383A
- Authority
- RU
- Russia
- Prior art keywords
- fusion protein
- modified
- amino acid
- heterologous
- linked glycosylation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 40
- 210000002966 serum Anatomy 0.000 title claims abstract 12
- 102000004169 proteins and genes Human genes 0.000 title claims 4
- 108090000623 proteins and genes Proteins 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title claims 2
- 108091006020 Fc-tagged proteins Proteins 0.000 claims abstract 37
- 230000004988 N-glycosylation Effects 0.000 claims abstract 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 17
- 102000039446 nucleic acids Human genes 0.000 claims abstract 9
- 108020004707 nucleic acids Proteins 0.000 claims abstract 9
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 9
- 108020001756 ligand binding domains Proteins 0.000 claims abstract 7
- 239000003446 ligand Substances 0.000 claims abstract 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000027455 binding Effects 0.000 claims abstract 4
- 238000004113 cell culture Methods 0.000 claims abstract 4
- 241000282693 Cercopithecidae Species 0.000 claims abstract 3
- 238000004458 analytical method Methods 0.000 claims abstract 3
- 230000004071 biological effect Effects 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 108020001507 fusion proteins Proteins 0.000 claims 33
- 102000037865 fusion proteins Human genes 0.000 claims 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 230000013595 glycosylation Effects 0.000 claims 15
- 238000006206 glycosylation reaction Methods 0.000 claims 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 11
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 10
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 239000004161 brilliant blue FCF Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000001279 glycosylating effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 102000027257 transmembrane receptors Human genes 0.000 claims 1
- 108091008578 transmembrane receptors Proteins 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26609509P | 2009-12-02 | 2009-12-02 | |
| US61/266,095 | 2009-12-02 | ||
| US32758210P | 2010-04-23 | 2010-04-23 | |
| US61/327,582 | 2010-04-23 | ||
| PCT/US2010/058765 WO2011068993A1 (en) | 2009-12-02 | 2010-12-02 | Compositions and methods for increasing serum half-life of fc fusion proteins. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012127383A true RU2012127383A (ru) | 2014-01-10 |
Family
ID=44115295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012127383/10A RU2012127383A (ru) | 2009-12-02 | 2010-12-02 | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8722615B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2507267B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013512674A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140015152A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102770458A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010325943A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012013330A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2782320A1 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2012DN05169A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2012127383A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011068993A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| RU2012127383A (ru) | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
| WO2012170938A1 (en) * | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
| US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| CA2878992C (en) * | 2012-07-18 | 2020-09-22 | Apogenix Gmbh | Composition comprising a mixture of cd95-fc isoforms |
| US9550820B2 (en) | 2013-02-22 | 2017-01-24 | New York University | Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
| EP2969009B1 (en) * | 2013-03-15 | 2018-11-28 | Pyranose Biotherapeutics, Inc. | Modified fc fusion proteins |
| GB201316592D0 (en) * | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| PL3063275T3 (pl) | 2013-10-31 | 2020-03-31 | Resolve Therapeutics, Llc | Terapeutyczne fuzje nukleaza-albumina i sposoby |
| CA2938066C (en) | 2014-02-02 | 2025-05-06 | Medimmune Limited | CHIMERIC PROTEIN COMPOSED OF NERVE GROWTH FACTOR ANTAGONIST DOMAIN AND TUMOR NECROSIS FACTOR-ANTAGONIST DOMAIN-A |
| JP2017517272A (ja) * | 2014-03-28 | 2017-06-29 | ニューヨーク・ユニバーシティ | Ｆｇｆ２３融合タンパク質 |
| CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
| WO2016069889A1 (en) | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Therapeutic nuclease-transferrin fusions and methods |
| JP2018510637A (ja) | 2015-03-26 | 2018-04-19 | アクセルロン ファーマ， インコーポレイテッド | フォリスタチン関連融合タンパク質およびその使用 |
| US10781246B2 (en) | 2015-06-05 | 2020-09-22 | New York University | Compositions and methods for anti-staphylococcal biologic agents |
| WO2017023855A1 (en) * | 2015-07-31 | 2017-02-09 | The General Hospital Corporation | Protein prostheses for mitochondrial diseases or conditions |
| US10988543B2 (en) * | 2015-11-11 | 2021-04-27 | Opi Vi—Ip Holdco Llc | Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor |
| CN119120423A (zh) | 2016-07-01 | 2024-12-13 | 分解治疗有限责任公司 | 优化的二核酸酶融合体和方法 |
| EP3672986A1 (en) | 2017-08-22 | 2020-07-01 | Sanabio, LLC | Soluble interferon receptors and uses thereof |
| JP2021535746A (ja) * | 2018-09-05 | 2021-12-23 | エルジー・ケム・リミテッド | Ｏ−グリコシル化可能なポリペプチド領域を含む融合ポリペプチド |
| CA3124352A1 (en) | 2019-01-04 | 2020-07-09 | Resolve Therapeutics, Llc | Treatment of sjogren's disease with nuclease fusion proteins |
| CA3165342A1 (en) | 2020-06-29 | 2022-01-06 | James Arthur Posada | Treatment of sjogren's syndrome with nuclease fusion proteins |
| WO2025147696A1 (en) | 2024-01-05 | 2025-07-10 | Resolve Therapeutics, Llc | Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5945397A (en) | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| JP3122139B2 (ja) | 1991-10-15 | 2001-01-09 | マラーキー，ミッシェル，エフ． | 後期段階炎症反応の治療用組成物 |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| WO1995026985A1 (en) | 1994-04-05 | 1995-10-12 | Board Of Regents, The University Of Texas System | Modified receptors that continuously signal |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| EP0822984A4 (en) | 1995-04-27 | 2000-05-03 | Human Genome Sciences Inc | TUMOR NECROSIS FACTOR RECEPTORS IN MEN |
| US7070783B1 (en) | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US5570401A (en) * | 1995-09-22 | 1996-10-29 | General Electric Company | BWR containment configuration having partitioned wetwell airspace |
| JP2001513754A (ja) | 1996-12-06 | 2001-09-04 | アムジェン インコーポレイテッド | Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療 |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
| WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| WO1999011662A1 (en) | 1997-09-05 | 1999-03-11 | Millennium Biotherapeutics, Inc. | Novel molecules of the tnfr-ligand-related protein family and uses thereof |
| WO1999023879A1 (en) | 1997-11-07 | 1999-05-20 | Uab Research Foundation | Method for the augmentation of gene expression |
| US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
| CA2321105A1 (en) | 1998-02-17 | 1999-08-19 | Incyte Pharmaceuticals, Inc. | Human short-chain tnf-receptor family protein |
| BR9908226A (pt) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| WO1999045009A1 (en) | 1998-03-04 | 1999-09-10 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| WO1999053059A1 (en) * | 1998-04-16 | 1999-10-21 | Genentech, Inc. | Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| SE9803710L (sv) | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
| CA2343840C (en) | 1998-10-20 | 2011-03-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of a cytokine-producing lactococcus strain to treat colitis |
| EP1126843A4 (en) | 1998-10-29 | 2005-06-15 | Bristol Myers Squibb Co | AMINO-CELL DERIVATIVE COMPOUNDS INHIBITORS OF ENZYME IMPDH |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| AU2000236029A1 (en) | 1999-02-23 | 2000-09-14 | Anne Chew | Receptor isogenes: polymorphisms in the tissue necrosis factor receptor |
| US20030148955A1 (en) | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| ATE348608T1 (de) | 1999-08-10 | 2007-01-15 | Glaxo Group Ltd | Ep4 rezeptor ligand und verwendung gegen neuropatischen schmerzen, colon krebs, hiv und migräne |
| CA2383073A1 (en) | 1999-08-25 | 2001-03-01 | Immunex Corporation | Compositions and methods for improved cell culture |
| GB9927681D0 (en) | 1999-11-23 | 2000-01-19 | Glaxo Group Ltd | Protein |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| US20020160416A1 (en) | 2000-02-11 | 2002-10-31 | Boyle William J. | Receptor from TNF family |
| JP2003525612A (ja) | 2000-03-02 | 2003-09-02 | ゼンコー | ＴＮＦ−α関連障害の処置のための変種ＴＮＦ−αタンパク質の設計および発見 |
| ES2266187T3 (es) | 2000-03-24 | 2007-03-01 | Genentech, Inc. | Uso de la insulina para el tratamiento de trastornos del cartilago. |
| US6800300B1 (en) | 2000-03-31 | 2004-10-05 | Vasogen Ireland Limited | Method for treating autoimmune and alloimmune diseases |
| EP1522590B1 (en) | 2000-06-28 | 2009-08-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| WO2002020762A2 (en) | 2000-09-05 | 2002-03-14 | Amgen Inc. | Tnf receptor-like molecules and uses thereof |
| US6610750B1 (en) | 2000-09-15 | 2003-08-26 | Laboratoires Negma | Treatment of osteoarthritis |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| US20020150582A1 (en) | 2001-02-08 | 2002-10-17 | Friedrichs Gregory S. | Method of treating or inhibiting cellular injury or cell death |
| PL374045A1 (en) | 2001-02-23 | 2005-09-19 | Immunex Corporation | Efficient recovery of correctly refolded proteins |
| US6972327B1 (en) | 2001-05-08 | 2005-12-06 | Immunex Corporation | Regeneration of chromatography material |
| KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| KR20050042062A (ko) | 2001-11-07 | 2005-05-04 | 에프. 호프만-라 로슈 아게 | 아미노피리미딘 및 피리딘 |
| EP1463942B2 (en) | 2001-12-21 | 2012-06-20 | Immunex Corporation | Methods for purifying protein |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PT1946776T (pt) | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| EP1497444B1 (en) | 2002-03-27 | 2015-11-04 | Immunex Corporation | Methods for increasing polypeptide production |
| US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
| US7067279B1 (en) | 2002-08-23 | 2006-06-27 | Immunex Corporation | Cell culture performance with betaine |
| US6974681B1 (en) | 2002-08-23 | 2005-12-13 | Immunex Corporation | Cell culture performance with vanadate |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
| US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| EP1636264A2 (en) | 2003-06-24 | 2006-03-22 | MERCK PATENT GmbH | Tumour necrosis factor receptor molecules with reduced immunogenicity |
| JP2007521315A (ja) | 2003-08-01 | 2007-08-02 | アムジェン インコーポレイテッド | 結晶性腫瘍壊死因子レセプター２ポリペプチド |
| WO2005014035A2 (en) | 2003-08-08 | 2005-02-17 | Novo Nordisk Health Care Ag | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| US7268116B2 (en) | 2003-10-02 | 2007-09-11 | Genhunter Corp. | Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins |
| KR20050082389A (ko) | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
| US7507745B2 (en) | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| WO2006001023A2 (en) | 2004-06-28 | 2006-01-05 | Yeda Research And Development Co. Ltd | Chimeric proteins and uses thereof |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| JP2008528006A (ja) | 2005-01-28 | 2008-07-31 | アポロ ライフ サイエンシズ リミテッド | 分子およびそのキメラ分子 |
| US8318699B2 (en) | 2005-01-31 | 2012-11-27 | The Trustees Of The University Of Pennsylvania | Tumor necrosis factor inhibitors |
| US7956160B2 (en) | 2005-07-22 | 2011-06-07 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
| CN1954882A (zh) | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
| US7626895B2 (en) | 2005-12-01 | 2009-12-01 | International Business Machines Corporation | Removable media battery pack for powering a media accessor of an automated data-storage library |
| AU2007309650A1 (en) | 2006-02-08 | 2008-05-02 | Ercole Biotech, Inc. | Soluble TNF receptors and their use in treatment of disease |
| US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
| ES2531934T3 (es) | 2006-09-01 | 2015-03-20 | Novo Nordisk Health Care Ag | Glicoproteínas modificadas |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| IL182956A0 (en) | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| CN101778937A (zh) | 2007-06-04 | 2010-07-14 | 诺和诺德公司 | 使用n-乙酰葡糖胺转移酶的o-联糖基化 |
| CA2720628A1 (en) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| CA2711503A1 (en) | 2008-01-08 | 2009-07-16 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| WO2010019261A1 (en) | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
| WO2010033854A2 (en) | 2008-09-19 | 2010-03-25 | Synageva Biopharma Corp. | Avian derived fusion proteins |
| US8178488B2 (en) * | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| BRPI1010704B1 (pt) | 2009-06-12 | 2021-12-14 | Acceleron Pharma Inc | Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma |
| RU2012127383A (ru) | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
| WO2012170938A1 (en) * | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
-
2010
- 2010-12-02 RU RU2012127383/10A patent/RU2012127383A/ru not_active Application Discontinuation
- 2010-12-02 CN CN2010800629282A patent/CN102770458A/zh active Pending
- 2010-12-02 US US12/959,220 patent/US8722615B2/en active Active
- 2010-12-02 WO PCT/US2010/058765 patent/WO2011068993A1/en not_active Ceased
- 2010-12-02 JP JP2012542194A patent/JP2013512674A/ja not_active Withdrawn
- 2010-12-02 AU AU2010325943A patent/AU2010325943A1/en not_active Abandoned
- 2010-12-02 IN IN5169DEN2012 patent/IN2012DN05169A/en unknown
- 2010-12-02 BR BR112012013330A patent/BR112012013330A2/pt not_active IP Right Cessation
- 2010-12-02 CA CA2782320A patent/CA2782320A1/en not_active Abandoned
- 2010-12-02 KR KR1020127017129A patent/KR20140015152A/ko not_active Withdrawn
- 2010-12-02 EP EP10835138.8A patent/EP2507267B1/en active Active
-
2014
- 2014-04-24 US US14/261,212 patent/US20150010555A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012013330A2 (pt) | 2017-03-28 |
| US20150010555A1 (en) | 2015-01-08 |
| CN102770458A (zh) | 2012-11-07 |
| EP2507267A1 (en) | 2012-10-10 |
| WO2011068993A1 (en) | 2011-06-09 |
| US20110171218A1 (en) | 2011-07-14 |
| CA2782320A1 (en) | 2011-06-09 |
| AU2010325943A1 (en) | 2012-06-21 |
| EP2507267B1 (en) | 2016-09-14 |
| IN2012DN05169A (cg-RX-API-DMAC7.html) | 2015-10-23 |
| KR20140015152A (ko) | 2014-02-06 |
| JP2013512674A (ja) | 2013-04-18 |
| EP2507267A4 (en) | 2013-05-29 |
| US8722615B2 (en) | 2014-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012127383A (ru) | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке | |
| JP7560507B2 (ja) | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 | |
| US9212231B2 (en) | TRAIL R2-specific multimeric scaffolds | |
| EP2858662B1 (en) | Fibroblast growth factor 21 proteins | |
| AU2012228990A1 (en) | Potent and selective inhibitors of Nav1.3 and Nav1.7 | |
| CN106457070A (zh) | 基于IL‑15/IL‑15Rα的缀合物的纯化方法 | |
| RU2006127554A (ru) | Fc-эритропоэтин слитый белок с улучшенной фармакокинетикой | |
| CN102875683B (zh) | 长效重组人生长激素的Fc融合蛋白 | |
| WO2021247675A9 (en) | Coronavirus-binding agents and uses thereof | |
| CN105916883B (zh) | 双功能融合蛋白及其制备方法和用途 | |
| JP7440516B2 (ja) | 切断多価多量体 | |
| JP5100662B2 (ja) | Ｂｍｐ−７変異体組成物、方法および使用 | |
| AU2020262424A1 (en) | CD80 variant proteins and uses thereof | |
| CN115073607A (zh) | Tnfr2与baff受体的融合蛋白 | |
| JP2009544325A (ja) | Ｂｍｐ−７変異体組成物、方法および使用 | |
| HK40090436A (zh) | Cd40l-特异性tn3-衍生的支架及其使用方法 | |
| HK1180695B (en) | Trail r2-specific multimeric scaffolds | |
| HK1180695A (en) | Trail r2-specific multimeric scaffolds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20131203 |